Cells comprising non-HLA restricted T cell receptors

US11229669B2 · kind B2 · utility

Assignee

• Memorial Sloan Kettering Cancer Center · US

Inventors

• Michel Sadelain · New York, US
• Jorge Mansilla-Soto · Queens, US
• Justin Eyquem · New York, US
• Anton Dobrin · New York, US

Key dates

• Filing date: Oct 20, 2020
• Grant date: Jan 25, 2022
• Expiry date: Oct 20, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.